Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

0.9973 -0.0027 (-0.27%)
Streaming Delayed Price Updated: 12:41 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Citizens And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
Via Benzinga
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial. 
Via InvestorPlace
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung disease. The study showed similar sputum culture conversion rates between... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; Trimble Issues Weak Outlook
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024. 
Via Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. (NASDAQ: MNDY) fell sharply in today’s pre-market trading after... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top 5 Health Care Stocks That May Dip
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Lennar To Rally Around 14%? Plus Keybanc Predicts $5,120 For This Stock
  Keybanc boosted the price target on Lennar Corporation (NYSE: LEN) from $89 to $100. Lennar shares fell 0.4% to close at $88.03 on Friday. 
Via Benzinga
Uber, Lyft, AZZ And Other Big Losers From Tuesday
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesday. 
Via Benzinga
Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.